期刊
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
卷 145, 期 4, 页码 483-486出版社
SPRINGER
DOI: 10.1007/s10517-008-0124-4
关键词
amyotrophic lateral sclerosis; gene therapy; adenoviral vector; VEGF; angiogenin
Two-year experiments were performed to evaluate the neurotrophic effect of hypoxia-inducible factors (vascular endothelial growth factor and angiogenin) expressed in recombinant human adenoviruses in amyotrophic lateral sclerosis. Randomized placebo-controlled trial demonstrated safety and good tolerability of the recombinant antiviral drugs. The life span of patients under conditions of hypoxia increased after treatment with the test drug, which was probably related to improved resistance of motoneurons. The presence of virus-neutralizing antibodies decreases the effectiveness of adenoviral vectors, which necessitates differential approach to the selection of patients and continuous monitoring of gene therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据